Applied dna announces first quarter fiscal year 2024 financial results

- company on track to initiate first-phase gmp production capacity for mrna critical starting materials during first half of calendar 2024, projects initial facility capacity to enable up to $15 million1 of linea ivt revenue2 annually - - conference call/webcast scheduled for today at 4:30 pm et - stony brook, ny / accesswire / february 8, 2024 / applied dna sciences, inc. (nasdaq:apdn) ("applied dna" or the "company"), a leader in pcr-based dna technologies, today announced consolidated financial results for its first fiscal quarter ended december 31, 2023. the company's form 10-q can be viewed at https://investors.adnas.com/sec-filings/.
APDN Ratings Summary
APDN Quant Ranking